{Reference Type}: Journal Article
{Title}: Patterns of platinum drug use in an acute care setting: a retrospective study.
{Author}: Armstrong-Gordon E;Gnjidic D;McLachlan AJ;Hosseini B;Grant A;Beale PJ;Wheate NJ;
{Journal}: J Cancer Res Clin Oncol
{Volume}: 144
{Issue}: 8
{Year}: Aug 2018
{Factor}: 4.322
{DOI}: 10.1007/s00432-018-2669-6
{Abstract}: <B>OBJECTIVE: </B>Platinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions.<BR><B>METHODS: </B>A retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015.<BR><B>RESULTS: </B>Of the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia.<BR><B>CONCLUSIONS: </B>The findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment.